[Secondary hyperlipoproteinemias].
At first the review deals with significance of the apoproteins for the metabolism of the lipoproteins, especially VLDL. Thus, for instance the apo-C is a cofactor for the lipase of the fatty tissue which hydrolyses the chylomicron-TG. The author enters examples of the secondary hyperlipoproteinaemias: hyperlipoproteinaemias in diseases of the liver and of the kidneys, in pancreatitis and in diabetes. In cholestasis an abnormal lipoprotein called LP-X is observed, in other diseases of the liver the beta2LP corresponding to the VLDL-intermediate. Causes for increases of lipoproteins in renal diseases are probably disturbances of the protein metabolism. There are close correlations between hyperlipoproteinaemias and pancreatitis. In diabetes primary hyperlipoproteinaemias in maturity-onset-diabetes are to be differed from clearly secondary ones in juvenile-onset-diabetes as well as such ones in nephropathy. The therapy of the secondary hyperlipoproteinaemias is shortly discussed.
D000208:Acute Disease; D002994:Clofibrate / Q000627:therapeutic use; D005260:Female; D006505:Hepatitis / Q000150:complications; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D007037:Hypothyroidism / Q000150:complications; D008079:Lipoproteins, VLDL / Q000378:metabolism; D009404:Nephrotic Syndrome / Q000150:complications; D010195:Pancreatitis / Q000150:complications; D011247:Pregnancy
D008079:Lipoproteins, VLDL; D002994:Clofibrate
Sekundre Hyperlipoproteinämien.